News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Catalyst Pharmaceutical Partners, Inc. (CPRX) Closes Previously Announced $15.1 Million Registered Direct Offering

9/10/2013 12:37:17 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CORAL GABLES, FL, September 10, 2013 -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq : CPRX) today reported that it has closed its prev iously announced offering of 8.8 million shares of its common stock in a registered direct public offering. The offering price was $1.72 per share, resulting in gross proceeds of approximate ly $15.1 million. Roth Capital Partners acted as the exclusive placement agent for the offeri ng and Aegis Capital Corp., Maxim Group LLC and H.C. Wainwright & Co. acted as financial advisers with respect to the offering.

Patrick J. McEnany, Catalyst's Chairman and CE O, stated: “We are pleased to have completed this financing, which we believe, along with the proceeds from recent warrant exercises, gives us the capital necessary to fund de velopment of Firdapse™ and allo ws us to begin new clinical studies for CPP-115." Mr. McEna ny continued: "We are also exci ted that several high quality fundamental life science investor s, including New Leaf Venture Pa rtners, particip ated in our offering."

Dr. Mark G. Charest of New Leaf Venture Partners, st ated: “New Leaf is pleased to support the development of Firdapse™ under the recently gr anted ‘Breakthrough Therapy Designation.’ We are excited about the po tential for Firdapse™.”

The shares were offered pursuant to a shelf re gistration statement on Form S-3 (File No. 333- 170945) filed pursuant to the Secu rities Act of 1933, as amended, which was previously filed with, and declared effective by, the Securities and Exchange Commission (SEC). A prospectus supplement relating to the offering has been file d with the SEC and is available on the SEC's website at

This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securi ties in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any su ch state or jurisdiction.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a specialty pharmaceutical company focused on the development and commercialization of novel prescription drugs targ eting rare (orphan) neuromuscular and neurological diseases, in cluding Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette Syndrome. Catalyst's lead candidate, Firdapse™ for the treatment of LEMS, is currently undergoing testing in a global, multi-center, pivotal phase III trial and recently received "Breakthrough Therapy Designation" from the U.S. Food & Drug Administration (FDA). Catalyst is also developing a potentially sa fer and more potent vigabatrin analog (designated CPP-115) to treat infantile spasms, and epile psy, as well as other neurological conditions associated with reduced GABAergic si gnaling, like post-traumatic stress disorder and Tourette Syndrome.

Forward-Looking Statements

This press release contains fo rward-looking statements. Forwar d-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actua l results in future periods to differ materially from forecasted resu lts. A number of factors, including the timing of completion of Catalyst's currently ongoing Phase III trial of Firdapse™, whether the Phase III trial will be successful, whether the receipt of breakthrough th erapy designation for Firdapse™ will expedite the development and review of Firdapse™ by the FDA or the likelihood that the product will be found to be safe and effective, wh ether the proceeds of this offering, along with the proceeds of recent warrant exercises, will be sufficient to fund the development of Firdapse™ and to begin new cl inical studies for CPP-115, whet her an NDA for Firdapse™ will ever be accepted for filing by the FDA, the timing of any such NDA filing or acceptance, whether, even if approved, Firdapse™ will be the only approved treatment option for LEMS patients, whether any of Catalyst's product candidates will ever be approved for commercialization or successfully commercializ ed, and those other f actors described in Catalyst's Annual Report on Form 10-K for the fis cal year 2012 and other filings with the U.S. Securities and Exchange Commis sion (SEC), could adversely a ffect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus